Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol
Mitral valve disease (MVD) is a progressive disease that can reduce cardiac output. Activation of the sympathetic autonomic nervous system is one of the body’s first responses in order to maintain cardiac output, but may have deleterious effects on the cardiovascular system. This study investigated...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | Brasil |
| Institución: | Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) |
| Repositorio: | Brazilian Journal of Veterinary Medicine |
| Idioma: | inglés |
| OAI Identifier: | oai:ojs.rbmv.org:article/1192 |
| Acceso en línea: | https://bjvm.org.br/BJVM/article/view/1192 |
| Access Level: | acceso abierto |
| Palabra clave: | sistema nervoso autônomo, betabloqueadores, holter, pNN50 autonomic nervous system, beta-blockers, holter, pNN50. |
| id |
BR_593c704ebcd89264dfd84083bbbd40fa |
|---|---|
| oai_identifier_str |
oai:ojs.rbmv.org:article/1192 |
| network_acronym_str |
BR |
| network_name_str |
Brasil |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol Variabilidade da frequência cardíaca e qualidade de vida em cães com doença valvar mitral tratados com metoprolol |
| title |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol |
| spellingShingle |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol Beluque, Tamyris sistema nervoso autônomo, betabloqueadores, holter, pNN50 autonomic nervous system, beta-blockers, holter, pNN50. |
| title_short |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol |
| title_full |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol |
| title_fullStr |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol |
| title_full_unstemmed |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol |
| title_sort |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol |
| dc.creator.none.fl_str_mv |
Beluque, Tamyris Camacho, Aparecido Antonio Ampuero, Roberto Navarrete Braz, Jaislane Bastos Kirnew, Murillo Daparé Canola, Raphaela Arantes Marques Carvalho, Elizabeth Sousa, Marlos Gonçalves |
| author |
Beluque, Tamyris |
| author_facet |
Beluque, Tamyris Camacho, Aparecido Antonio Ampuero, Roberto Navarrete Braz, Jaislane Bastos Kirnew, Murillo Daparé Canola, Raphaela Arantes Marques Carvalho, Elizabeth Sousa, Marlos Gonçalves |
| author_role |
author |
| author2 |
Camacho, Aparecido Antonio Ampuero, Roberto Navarrete Braz, Jaislane Bastos Kirnew, Murillo Daparé Canola, Raphaela Arantes Marques Carvalho, Elizabeth Sousa, Marlos Gonçalves |
| author2_role |
author author author author author author author |
| dc.subject.por.fl_str_mv |
sistema nervoso autônomo, betabloqueadores, holter, pNN50 autonomic nervous system, beta-blockers, holter, pNN50. |
| topic |
sistema nervoso autônomo, betabloqueadores, holter, pNN50 autonomic nervous system, beta-blockers, holter, pNN50. |
| description |
Mitral valve disease (MVD) is a progressive disease that can reduce cardiac output. Activation of the sympathetic autonomic nervous system is one of the body’s first responses in order to maintain cardiac output, but may have deleterious effects on the cardiovascular system. This study investigated the effect of metoprolol on heart rate variability and quality of life in dogs with severe MVD (stage C, according to the guidelines of the American College of Veterinary Internal Medicine). Eight dogs between nine and thirteen years of age were enrolled and screening tests such as complete blood count, serum biochemistry profile, systolic blood pressure, thoracic radiographs, electrocardiogram, echocardiogram and long-term electrocardiography (24 hours) were performed. The patients were treated with enalapril, furosemide, spironolactone, and pimobendan until considered clinically stable, and metoprolol was then added to the therapy. One month later, all animals were re-assessed. Owners responded to a questionnaire about their dog’s quality of life before and after beta-blocker therapy. The value for pNN50 (percentage difference between adjacent N-N intervals more than 50 ms) was significantly higher (P=0.039) after treatment with metoprolol, indicating higher heart rate variability as indicated by the increased parasympathetic component. Furthermore, quality of life was improved in 30% of patients after metoprolol was initiated. The results suggest that treatment with beta-blockers in dogs with stage C MVD may yield additional benefits in comparison to standard CHF treatment. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-06-21 |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion peer reviewed Avaliado pelos pares |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
https://bjvm.org.br/BJVM/article/view/1192 10.29374/2527-2179.bjvm003020 |
| url |
https://bjvm.org.br/BJVM/article/view/1192 |
| identifier_str_mv |
10.29374/2527-2179.bjvm003020 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
https://bjvm.org.br/BJVM/article/view/1192/1092 https://bjvm.org.br/BJVM/article/view/1192/1217 |
| dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0 |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf text/xml |
| dc.publisher.none.fl_str_mv |
Sociedade de Medicina Veterinária do Estado do Rio de Janeiro. |
| publisher.none.fl_str_mv |
Sociedade de Medicina Veterinária do Estado do Rio de Janeiro. |
| dc.source.none.fl_str_mv |
Brazilian Journal of Veterinary Medicine; Vol. 43 No. 1 (2021); e003020 Revista Brasileira de Medicina Veterinária; v. 43 n. 1 (2021); e003020 2527-2179 0100-2430 reponame:Brazilian Journal of Veterinary Medicine instname:Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) instacron:SBMV |
| instname_str |
Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) |
| instacron_str |
SBMV |
| institution |
SBMV |
| reponame_str |
Brazilian Journal of Veterinary Medicine |
| collection |
Brazilian Journal of Veterinary Medicine |
| repository.name.fl_str_mv |
Brazilian Journal of Veterinary Medicine - Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ) |
| repository.mail.fl_str_mv |
contato.rbmv@gmail.com |
| _version_ |
1853661254425509888 |
| spelling |
Heart rate variability and quality of life in dogs with mitral valve disease treated with metoprolol Variabilidade da frequência cardíaca e qualidade de vida em cães com doença valvar mitral tratados com metoprolol sistema nervoso autônomo, betabloqueadores, holter, pNN50autonomic nervous system, beta-blockers, holter, pNN50.Mitral valve disease (MVD) is a progressive disease that can reduce cardiac output. Activation of the sympathetic autonomic nervous system is one of the body’s first responses in order to maintain cardiac output, but may have deleterious effects on the cardiovascular system. This study investigated the effect of metoprolol on heart rate variability and quality of life in dogs with severe MVD (stage C, according to the guidelines of the American College of Veterinary Internal Medicine). Eight dogs between nine and thirteen years of age were enrolled and screening tests such as complete blood count, serum biochemistry profile, systolic blood pressure, thoracic radiographs, electrocardiogram, echocardiogram and long-term electrocardiography (24 hours) were performed. The patients were treated with enalapril, furosemide, spironolactone, and pimobendan until considered clinically stable, and metoprolol was then added to the therapy. One month later, all animals were re-assessed. Owners responded to a questionnaire about their dog’s quality of life before and after beta-blocker therapy. The value for pNN50 (percentage difference between adjacent N-N intervals more than 50 ms) was significantly higher (P=0.039) after treatment with metoprolol, indicating higher heart rate variability as indicated by the increased parasympathetic component. Furthermore, quality of life was improved in 30% of patients after metoprolol was initiated. The results suggest that treatment with beta-blockers in dogs with stage C MVD may yield additional benefits in comparison to standard CHF treatment.A doença valvar mitral (DVM) é progressiva e pode levar à redução do débito cardíaco. A ativação do sistema nervoso autônomo simpático é uma das primeiras tentativas para manter o débito cardíaco, no entanto pode culminar em efeitos deletérios para o sistema cardiovascular quando ativada de forma crônica. Este estudo investigou o efeito do metoprolol na variabilidade da frequência cardíaca e qualidade de vida de cães com DVM em estágio C, seguindo a classificação do American College of Veterinary Internal Medicine. Foram avaliados oito cães entre nove e treze anos com DVM de classe C. Foram realizados exames de triagem, tais como hemograma, perfil bioquímico sérico, aferição da pressão arterial sistólica, radiografias torácicas, eletrocardiograma, ecocardiograma e eletrocardiograma de longa duração (24 horas). Os pacientes foram tratados com enalapril, espironolactona, furosemida e pimobendan até a estabilização do quadro e, após, receberam metoprolol durante um mês para então serem submetidos aos mesmos exames. Os tutores responderam um questionário sobre a qualidade de vida de seus cães antes e após a terapia com o betabloqueador. O pNN50 (porcentagem dos intervalos RR adjacentes com diferença de duração maior que 50ms) apresentou aumento significativo (P=0.039) após o tratamento com metoprolol, indicando maior variabilidade da frequência cardíaca por permitir a prevalência do sistema nervoso autônomo parassimpático. Além disso, 30% dos pacientes apresentaram melhora na qualidade de vida após instituição do metoprolol. Considerando os resultados obtidos é possível inferir que o tratamento com o betabloqueador em cães com doença valvar mitral pode ser considerado uma ferramenta terapêutica adicional na terapia da insuficiência cardíaca congestiva classe C.Sociedade de Medicina Veterinária do Estado do Rio de Janeiro.2021-06-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionpeer reviewedAvaliado pelos paresapplication/pdftext/xmlhttps://bjvm.org.br/BJVM/article/view/119210.29374/2527-2179.bjvm003020Brazilian Journal of Veterinary Medicine; Vol. 43 No. 1 (2021); e003020Revista Brasileira de Medicina Veterinária; v. 43 n. 1 (2021); e0030202527-21790100-2430reponame:Brazilian Journal of Veterinary Medicineinstname:Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)instacron:SBMVenghttps://bjvm.org.br/BJVM/article/view/1192/1092https://bjvm.org.br/BJVM/article/view/1192/1217Copyright (c) 2021 Tamyris Beluque, Aparecido Antonio Camacho, Roberto Navarrete Ampuero, Jaislane Bastos Braz, Murillo Daparé Kirnew, Raphaela Arantes Marques Canola, Elizabeth Carvalho, Marlos Gonçalves Sousahttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBeluque, TamyrisCamacho, Aparecido AntonioAmpuero, Roberto NavarreteBraz, Jaislane BastosKirnew, Murillo DaparéCanola, Raphaela Arantes MarquesCarvalho, ElizabethSousa, Marlos Gonçalves2024-07-16T07:49:39Zoai:ojs.rbmv.org:article/1192Revistahttps://rbmv.org/BJVMONGhttps://rbmv.org/BJVM/oaicontato.rbmv@gmail.com2527-21790100-2430opendoar:2024-07-16T07:49:39Brazilian Journal of Veterinary Medicine - Sociedade de Medicina Veterinária do Estado do Rio de Janeiro (SOMVERJ)false |
| score |
15,301603 |